SCHEMBL303882

SCHEMBL303882

COCCNC(=O)c1cccc(N(Cc2ccc(Cl)cc2)S(=O)(=O)c2ccn(C)n2)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.40
DRD4 P21917 2/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 1/20 0.39
HPGD P15428 2/20 0.39
LMNA P02545 3/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 3/20 0.38
TSHR P16473 1/20 0.38
CXCR3 P49682 1/20 0.37
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
DRD2 P14416 1/20 0.37
PMP22 Q01453 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL304312 0.91 KMT2A (0.40) KMT2ADRD4MEN1ALDH1A1LMNA
SCHEMBL303301 0.90 MEN1 (0.41) KMT2AMEN1ALDH1A1LMNAPOLB
SCHEMBL2211916 0.88 MEN1 (0.42) KMT2AMEN1ALDH1A1LMNAPOLB
SCHEMBL303432 0.87 LMNA (0.42) KMT2AMEN1ALDH1A1LMNAPOLB
SCHEMBL3378801 0.86 PIK3CG (0.43) KMT2ADRD4MEN1ALDH1A1HPGD
SCHEMBL2214837 0.85 MEN1 (0.44) KMT2ADRD4MEN1ALDH1A1KDM4E
SCHEMBL2212260 0.85 LMNA (0.40) KMT2AMEN1ALDH1A1HPGDLMNA
SCHEMBL2214180 0.85 MEN1 (0.54) KMT2AMEN1ALDH1A1LMNAPOLB
SCHEMBL3377043 0.84 MEN1 (0.47) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL302949 0.84 MEN1 (0.49) KMT2AMEN1ALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP claimed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US claimed
JP-2012500836-A 2012-01-12 JP claimed
EP-2342177-A1 NOVEL POTASSIUM CHANNEL BLOCKERS Xention Limited (GB) 2011-07-13 EP claimed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023448-A1 NOVEL POTASSIUM CHANNEL BLOCKERS XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP disclosed
EP-2342177-A1 NOVEL POTASSIUM CHANNEL BLOCKERS Xention Limited (GB) 2011-07-13 EP disclosed
WO-2010023448-A1 NOVEL POTASSIUM CHANNEL BLOCKERS XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 KMT2A 1511/4885DRD4 446/4885MEN1 2747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.